GF 109203X
SIGMA/G2911 - synthetic, ≥90% (HPLC)
Synonym: 3-
CAS Number: 133052-90-1
Empirical Formula (Hill Notation): C25H24N4O2
Molecular Weight: 412.48
MDL Number: MFCD00236428
Linear Formula: C25H24N4O2
Product Type: Chemical
| assay | ≥90% (HPLC) |
| biological source | synthetic |
| InChI | 1S/C25H24N4O2/c1-28(2)12- |
| InChI key | QMGUOJYZJKLOLH-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | CN(C)CCCn1cc(C2=C(C(=O)NC |
| solubility | DMSO: soluble (~1 mg/ml) |
| storage temp. | 2-8°C |
| Application: | GF 109203X has been used as a protein kinase C inhibitor in HUVECs (human umbilical vein endothelial cells), angiotensinogen gene knockout (AGT KO) mice, and in granulosa cell cultures of female rats. |
| Biochem/physiol Actions: | A potent and selective competitive inhibitor of protein kinase C (PKC) and of glycogen synthase kinase-3 (GSK-3). In certain cells, inhibition of PKC leads to an increase in autophagy. For PKC inhibition, typically used at a concentration of 0.1-10 μM. |
| Biochem/physiol Actions: | A potent and selective competitive inhibitor of protein kinase C (PKC) and of glycogen synthase kinase-3 (GSK-3). Inhibits parathyroid hormone-induced Ca2+ resorption from isolated bone tissue, Staurosporine, another protein kinase inhibitor, actually enhanced Ca2+ resorption elicited by a number of agents, but GF109203X counteracted that enhancement. |
| Preparation Note: | For PKC inhibition, typically used at a concentration of 0.1-10 μM. |
| Symbol |  GHS08 |
| Signal word | Warning |
| Hazard statements | H351 |
| Precautionary statements | P201 - P202 - P280 - P308 + P313 - P405 - P501 |
| Hazard Codes | Xn |
| Risk Statements | 22-40 |
| Safety Statements | 36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Supplemental Hazard Statements | EUH019 |
| Purity | ≥90% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352202 |